Introduction: Metabolic syndrome (MetS) is defined as a cluster of risk factors for cardiovascular disease. Aim of this study was to evaluate the association between metabolic syndrome components (ATPIII) and the presence of two common polymorphisms (Pro12Ala and ACE I/D) in a cohort of obese individuals. Materials and methods: 140 subjects (M/F= 44/96) underwent a clinical and biochemical evaluation for the identification of ATPIII metabolic syndrome components. Pro12Ala polymorphism was assessed by PCR-RFPL, while ACE I/D genotype was assessed by PCR of fragment containing the insertion/deletion. Results: Prevalence of metabolic syndrome in our population was 29.7% with an higher prevalence in men compared to women (M 36.3%, F26.6%). ACE I/D polymorphism was distributed as following: DD 37.9%, ID 45%, II 17.1%. Only 12% of the population was carrier of the Ala allele in PPARgamma gene. No difference was found in distribution of the Pro12Ala polymorphism nor the ACE I/D polymorphism among patients with or without MetS. MetS components and ACE I/D polymorphism were not significantly associated. Subjects carrying the Ala allele showed a significantly higher body mass index (BMI) despite not having a larger waist or an higher fat mass, when assessed by impedance analysis. Conclusions: we failed to find an association between ACE I/D polymorphism and metabolic syndrome while presence of the Ala allele in PPARgamma gene seems to be associated with an higher BMI but comparable index of visceral adiposity. We hypothesize a protec
Association between ACE gene Insertion/Deletion (ACE I/D) polymorphism, PPAR-gamma Pro12Ala (Pro12Ala) polymorphism and ATPIII metabolic syndrome components in a cohort of obese subjects.
DALLA NORA, Edoardo;PASSARO, Angelina;MARCELLO, Maria Caterina;MARI, Elisa;FELLIN, Renato
2007
Abstract
Introduction: Metabolic syndrome (MetS) is defined as a cluster of risk factors for cardiovascular disease. Aim of this study was to evaluate the association between metabolic syndrome components (ATPIII) and the presence of two common polymorphisms (Pro12Ala and ACE I/D) in a cohort of obese individuals. Materials and methods: 140 subjects (M/F= 44/96) underwent a clinical and biochemical evaluation for the identification of ATPIII metabolic syndrome components. Pro12Ala polymorphism was assessed by PCR-RFPL, while ACE I/D genotype was assessed by PCR of fragment containing the insertion/deletion. Results: Prevalence of metabolic syndrome in our population was 29.7% with an higher prevalence in men compared to women (M 36.3%, F26.6%). ACE I/D polymorphism was distributed as following: DD 37.9%, ID 45%, II 17.1%. Only 12% of the population was carrier of the Ala allele in PPARgamma gene. No difference was found in distribution of the Pro12Ala polymorphism nor the ACE I/D polymorphism among patients with or without MetS. MetS components and ACE I/D polymorphism were not significantly associated. Subjects carrying the Ala allele showed a significantly higher body mass index (BMI) despite not having a larger waist or an higher fat mass, when assessed by impedance analysis. Conclusions: we failed to find an association between ACE I/D polymorphism and metabolic syndrome while presence of the Ala allele in PPARgamma gene seems to be associated with an higher BMI but comparable index of visceral adiposity. We hypothesize a protecI documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
